Cladaxxa 400 mg/100 mg Chewable Tablets for Dogs

Authorised

- Amoxicillin trihydrate
- Potassium clavulanate

Product identification

Medicine name:
Cladaxxa 400 mg/100 mg Chewable Tablets for Dogs

Active substance:
Amoxicillin trihydrate

Potassium clavulanate

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Amoxicillin trihydrate
459.22 milligram(s) / 1.00 Tablet

Potassium clavulanate

119.13 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01CR02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
United Kingdom (Northern Ireland)

Package description:
Blister formed of an aluminium foil which consists of aluminum layer coated with OPA (Oriented Polyamide) film on one side and PE with desiccant on the other side and an aluminium sealing foil which consists of aluminium layer and PE coating.Blister contains 6 tablets. Carton contains 12 tablets
Blister formed of an aluminium foil which consists of aluminum layer coated with OPA (Oriented Polyamide) film on one side and PE with desiccant on the other side and an aluminium sealing foil which consists of aluminium layer and PE coating.Blister contains 6 tablets. Carton contains 60 tablets
Blister formed of an aluminium foil which consists of aluminum layer coated with OPA (Oriented Polyamide) film on one side and PE with desiccant on the other side and an aluminium sealing foil which consists of aluminium layer and PE coating.Blister contains 6 tablets. Carton contains 300 tablets

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:
18/06/2021

Manufacturing sites for batch release:
KRKA tovarna zdravil d.d. Novo mesto

Responsible authority:
The Veterinary Medicines Directorate

Authorisation number:
Vm 01656/4202

Date of authorisation status change:
26/11/2024

Reference member state:
Ireland

Procedure number:
IE/V/0652/003

Concerned member states:
Belgium Croatia Czechia Estonia France Germany Hungary Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics